B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, recently launched Piperacillin and Tazobactam, one of the most utilized injectable antibiotics in the U.S., for use in the Company’s DUPLEX Drug Delivery System. Piperacillin and Tazobactam for Injection and Sodium Chloride Injection is available in three strengths—2.25 g/50 mL, 3.375 g/50 mL and 4.5 g/100 mL.
Health Technology Insights: MaxHSA and Avidia Health Announce Strategic Partnership to Help Increase HSA Deposits
This launch follows B. Braun’s recent Nurse Approved Certification for Piperacillin and Tazobactam in the DUPLEX Drug Delivery System, along with its full IV solutions portfolio and plastic irrigation containers. The certification underscores the company’s commitment to usability, workflow and alignment with nursing practice needs.
Health Technology Insights: PAICON Advances Global Cancer AI With Diverse Data
Piperacillin and Tazobactam in the DUPLEX Drug Delivery System is a ready-to-activate, two-compartment container—not made with DEHP or PVC—that keeps pre-measured medication and diluent separate until the provider is ready to administer at the bedside by simply folding, squeezing and shaking to reconstitute. This system reduces overall process time by nearly four minutes per dose and shows substantial labor time savings compared to both the Baxter Mini-Bag Plus Container System and traditional compounding, offering healthcare professionals a new and efficient way to administer this critical antibiotic combination.2
DUPLEX is also designed to reduce contamination risks and medication errors. The closed-system design helps protect potency and ensures the diluent cannot be delivered without the drug. Furthermore, DUPLEX decreases the likelihood of medication errors by 54% compared to traditional compounding methods based on fewer process steps.2 DUPLEX requires no thawing and can be stored at room temperature or in automated dispensing cabinets.
“The launch of Piperacillin and Tazobactam in the DUPLEX Drug Delivery System reinforces B. Braun’s commitment to supporting healthcare professionals with ready-to-activate antibiotic options,” said Ellen Menard, Corporate Vice President, Marketing Pharma at B. Braun Medical. “This product is designed to help reduce waste, save space and streamline preparation and administration—key advantages for busy pharmacy and nursing teams administering high-demand antibiotics.”
Piperacillin and Tazobactam in the DUPLEX Drug Delivery System is one of many planned injectable drugs B. Braun will launch in the U.S. in the next several years to expand its portfolio and help meet the needs of patients for medications in high demand.
Health Technology Insights: Jesper Høiland Joins Alva Therapeutics Board
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- PR Newswire
